BHV-1300 IgG Bispecific Degrader
BHV-1300 is the lead asset using a novel Molecular Degrader of ExtracellularProtein (“MoDE”) platform technology. BHV-1300 is a potent extracellular Pan-IgG lowering agent with an innovative mechanism of degrading and depleting pathogenic IgG in chronic and acute conditions rather than inhibition. IgG-specificity with BHV-1300 leads to improvements in disease targeting without unintended consequences on other antibodies.
With a differentiated profile, BHV-1300 has the potential for use in various indications, including, but not limited to, neurological disorders, cancer, infectious and autoimmune diseases.
